The EPS miss and widening losses are negative, but the strong cash position and Phase 3 Duchenne trial progress provide a floor. Watch for FDA guidance on accelerated approval for SGT-003 and initial FALCON data by year-end 2026 as potential catalysts.
SLDB drugs
SLDB drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 13 $7.38entry
- T+1 · 6mo ago 0.00%α +0.00% · $7.38
- T+5 · 6mo ago −17.62%α −16.46% · $6.08
- T+20 · 5mo ago −2.17%α −1.56% · $7.22
- T+60 · 3mo ago +13.69%α +9.25% · $8.39
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Solid Biosciences reported Q1 2026 EPS of -$0.53, a 20.9% miss versus the -$0.44 consensus, with net loss widening to $56.7M from $39.3M a year ago. The company highlighted Phase 3 Duchenne trial initiation and a strong cash position of $380.7M extending into H1 2028, but the earnings miss and rising R&D costs overshadow pipeline progress.
Key Financial Metrics
Key Facts
- Q1 2026 EPS of -$0.53 missed consensus of -$0.44 by 20.9%
- Net loss widened to $56.7M from $39.3M in Q1 2025
- Cash, cash equivalents and securities totaled $380.7M as of March 31, 2026, up from $187.9M at year-end 2025
- R&D expenses rose to $46.1M from $30.9M, driven by SGT-003 manufacturing and clinical costs
- First participant dosed in Phase 3 IMPACT DUCHENNE trial for SGT-003
- 47 participants dosed in Phase 1/2 INSPIRE DUCHENNE trial as of May 11, 2026
- Two participants dosed in Phase 1b FALCON trial for Friedreich's ataxia; no serious adverse events
- Cash runway expected into H1 2028
Financial Impact
EPS miss of 20.9% vs consensus; net loss increased 44.4% YoY to $56.7M
Risk Factors
- Continued cash burn with no near-term revenue; R&D costs may rise further
- Regulatory setbacks or delays in SGT-003 accelerated approval pathway
- Competition from other Duchenne gene therapies (e.g., Pfizer, Sarepta)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293411 |
Track record
14 reports on SLDB
4 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +20.77% at T+20 after the Mar 19, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $6.84 Now $6.48 −5.26% settles Dec 15
- Nov 6, 202610d ago SC 13D/A Neutral 3/10 Entry $7.02 Now $6.48 −7.69% settles Dec 8
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $6.18 Now $6.48 +4.85% settles Dec 4
- Aug 6, 202614w ago S-3ASR Neutral 4/10 Entry $8.39 to $10.25 Now $6.48 −22.77% ▲ +22.17% +22.57% vs SPY
- May 12, 202626w ago Press Release Bearish 6/10 Viewing Entry $7.38 to $7.22 Now $6.48 +12.20% ▲ +2.17% +1.56% vs SPY
- May 7, 202627w ago Press Release Bullish 7/10 Entry $7.07 to $6.85 Now $6.48 −8.35% ▼ −3.11% −6.25% vs SPY
- Apr 23, 202629w ago DEFA14A Neutral 3/10 Entry $7.92 to $6.50 Now $6.48 −18.18% ▼ −17.93% −21.96% vs SPY
- Apr 10, 202631w ago 8-K Neutral 2/10 Entry $8.39 to $7.68 Now $6.48 −22.77% ▼ −8.46% −16.19% vs SPY
- Apr 1, 202632w ago EFFECT Bearish 7/10 Entry $7.38 to $7.05 Now $6.48 +12.20% ▲ +4.47% +14.19% vs SPY
- Mar 19, 202634w ago Press Release Bullish 8/10 Entry $7.03 to $8.49 Now $6.48 −7.82% ▲ +20.77% +11.45% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers